Dementia

If you are suffering of mild cognitive impairment or symptoms of early dementia, you may benefit from participating in one of our clinical trials, which offer you treatment with novel substances that have not yet reached market approval and can therefore not be prescribed otherwise.

Regarding Alzheimer’s disease, we are currently performing the following clinical trials:

Anavex

A Phase 2b/3, Double-Blind, Randomised, Placebo-Controlled 48-week Safety and Efficacy trial of ANAVEX2-73 for the Treatment of Early Alzheimer’s Disease (AD).

You might consider study participation if the following inclusion criteria apply:

• You have been diagnosed with mild cognitive impairment or early Alzheimer’s disease.
• You are between 60 and 85 years of age.
• A caregiver is available and willing to accompany you to the study visits or is available for telephone queries.

Duration of Study: 48 weeks

We will gladly discuss further in- and exclusion criteria as well as study procedures during a personal meeting.

Graduate

An open-label, multicenter, rollover study to evaluate the safety, tolerability and efficacy of long-term gantenerumab administration in participants with Alzheimer’s disease.

Study enrollment has ended. This study has added to our portfolio solely for the sake of completeness.

For further information, please contact our site staff:

Dinah Schramm, telephone number: 06131-17-6101,
 dinah.schramm@unimedizin-mainz.de

and/or

Ricarda Endler, telephone number: 06131-17-6102,
 ricarda.endler@unimedizin-mainz.de

or

or get in touch with us via our general e-mail address:
 SPE@unimedizin-mainz.de

University Medical Center Mainz
Study Center for Clinical Trials in Mental Disorders
Untere Zahlbacher Str. 8
55131 Mainz
Germany